Considerations for Evaluating Treatment Effects From Randomized Clinical Trials

Clinical Pharmacology and Therapeutics

Volumn 102, Issue 6, 2017, Pages 917-923

  Ruberg, Stephen J ^a   Akacha, Mouna ^b  

^a ELI LILLY AND COMPANY   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL DECISION MAKING; CLINICAL EVALUATION; CLINICAL RESEARCH; DRUG INDUSTRY; HEALTH CARE PERSONNEL; INTENTION TO TREAT ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); THERAPY EFFECT; TREATMENT WITHDRAWAL; HUMAN; PROCEDURES; STATISTICS;

HUMANS; INTENTION TO TREAT ANALYSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STATISTICS AS TOPIC;

EID: 85030662323     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.869     Document Type: Article

References (24)

1. Fisher, L.D. et al. Intention to treat in clinical trials. In Statistical Issues in Drug Research and Development (ed. Peace, K.E.) 331–350 (Marcel Dekker, New York; 1990).
2. International Conference on Harmonisation. ICH Harmonised Tripartite Guideline: Statistical principles for clinical trials E9. . Accessed June 1, 2015.
3. Hollis, S. & Campbell, F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 319, 670–674 (1999).
4. Keene, O.N. Intent-to-treat analysis in the presence of off-treatment or missing data. Pharm. Stat. 10, 191–195 (2011).
5. Hernán, M.A., Hernández-Díaz, S. & Robins, J.M. Randomized trials analyzed as observational studies. Ann. Intern. Med. 159, 560–562 (2013).
6. Akacha, M., Bretz, F. & Ruberg, S.J. Estimands in clinical trials — broadening the perspective. Stat. Med. 36, 5–19 (2017).
7. Vrijens, B. & Urquhart, J. Methods for measuring, enhancing, and accounting for medication adherence in clinical trials. Clin. Pharmacol. Ther. 95, 617–626 (2014).
8. Breckenridge, A. et al. Poor medication adherence in clinical trials: consequences and solutions. Nat. Rev. Drug Discov. 16, 149–150 (2017).
9. National Research Council, Panel on Handling Missing Data in Clinical Trials, Committee on National Statistics, Division of Behavioral and Social Sciences and Education. In The Prevention and Treatment of Missing Data in Clinical Trials (National Academies Press, Washington, DC; 2010).
10. International Conference on Harmonisation. ICH Final Concept Paper E9(R1): Addendum to Statistical Principles for Clinical Trials on Choosing Appropriate Estimands and Defining Sensitivity Analyses in Clinical Trials. . Accessed April 15, 2015.
11. Akacha, M. & Kothny, W. Opinion paper on estimands: Opportunities and challenges. Clin. Pharmacol. Ther. (this issue) (2017).
12. Mallinckrodt, C.H. Preventing and Treating Missing Data in Longitudinal Clinical Trials: A Practical Guide (Cambridge University Press, New York; 2013).
13. International Conference on Harmonisation. Draft ICH E9 (R1) Technical Document: Addendum on Estimands and Sensitivity Analysis in Clinical Trials to the Guideline on Statistical Principles for Clinical Trials. . Accessed on 18 Sep 2017.
14. Little, R. & Kang, S. Intention-to-treat analysis with treatment discontinuation and missing data in clinical trials. Stat. Med. 34, 2381–2390 (2015).
15. Mallinckrodt, C., Molenberghs, G. & Rathmanna, S. Choosing estimands in clinical trials with missing data. Pharm. Stat. 16, 29–36 (2017).
16. Permutt, T. A taxonomy of estimands for regulatory clinical trials with discontinuations. Stat. Med. 35, 2865–2875 (2016).
17. Leuchs, A.K., Zinserling, J., Brandt, A., Wirtz, D. & Benda, N. Choosing appropriate estimands in clinical trials. Ther. Innov. Regul. Sci. 49, 584–592 (2015).
18. Garrett, A. Choosing appropriate estimands in clinical trials (Leuchs et al.): Letter to the editor. Ther. Innov. Regul. Sci. 49, 601 (2015).
19. Phillips, A. et al. Estimands: discussion points from the PSI estimands and sensitivity expert group. Pharm. Stat. (2016) DOI: 10.1002/pst.1745 [Epub ahead of print].
20. Rubin, D. & Imbens, G. Causal Inference for Statistics, Social, and Biomedical Sciences: An Introduction. 1st ed (Cambridge University Press, Cambridge, UK; 2015).
21. Robins, J.M. & Greenland, S. Adjusting for differential rates of PCP prophylaxis in high- versus low-dose AZT treatment arms in an AIDS randomized trial. J. Am. Stat. Assoc. 89, 737–749 (1994).
22. Hernán, M.A. & Hernández-Díaz, S. Beyond the intention-to-treat in comparative effectiveness research. Clin. Trials. 9, 48–55 (2012).
23. Qu, Y., Fu, H., Luo, J. & Ruberg, S.J. A causal estimator for treatment effect in randomized controlled trials among those who adhere to an experimental treatment. Under review. Biometrics.
24. Foster, J.C., Taylor, J.M.G. & Ruberg, S.J. Subgroup identification from randomized clinical trials. Stat. Med. 30, 2867–2880 (2011).